Does The Feasibility Process Differ For Rare Diseases?

Mimi Ermens, senior director, clinical development operations, global feasibility and start-up support, at CSL Behring answers a question from the audience about whether there is a difference in how you should approach the feasibility process when dealing with rare diseases vs. common diseases.